Current Issue


Continuous glucose monitoring may help type 2 diabetes patients

An industry-funded trial found slight decreases in HbA1c among insulin-using patients with type 2 diabetes who tried continuous glucose monitoring, compared to usual care.

Type 1 diabetes associated with increased atrial fibrillation risk, particularly in women

Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.

Tool may help stratify risk for hypoglycemia-related ED and hospital use

The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.

MKSAP quiz: Kidney screening

This month's quiz asks readers to evaluate a 45-year-old man who had type 2 diabetes diagnosed three months ago and whose father who developed end-stage kidney disease due to diabetes.

Spotlight on the kidneys

Two recent studies analyzed the renal effects of medications for type 2 diabetes, one finding lower rates of acute kidney injury with sodium-glucose co-transporter-2 inhibitors and the other finding reduced onset of macroalbuminuria with liraglutide.

In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years

The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.

ADA issues updated position statement on hypertension and diabetes

The statement updates the American Diabetes Association's 2003 position statement on this topic and summarizes clinical trials of intensive hypertension treatment strategies.

Liraglutide gets new cardiovascular indication

The FDA approved a new indication for liraglutide to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.